Ascelia Pharma Q2 FY26 operating loss narrows to SEK 12.1 million; EPS improves to SEK -0.09

Reuters2026/08/20 05:32

By:Reuters

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Ascelia Pharma posted a Q2 operating loss of SEK 12.1 million, narrowing from SEK 23 million a year earlier.
Loss per share improved to SEK 0.09 from SEK 0.20 in the prior-year quarter.
Operating cash outflow totaled SEK 14 million, compared with SEK 18 million a year earlier; liquid assets and marketable securities fell to SEK 38 million.
FDA issued a Complete Response Letter for Orviglance’s NDA; a Type A meeting is scheduled for Sept. 9.
Cost-saving measures were launched to cut cash burn; management reiterated confidence in approvability backed by Phase 3 SPARKLE results.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascelia Pharma AB published the original content used to generate this news brief on August 20, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Ascelia Pharma Q2 FY26 operating loss narrows to SEK 12.1 million; EPS improves to SEK -0.09

You may also like

Crypto prices